Literature DB >> 26792259

Bone Disease in Myeloma: The Claws of CRAB.

Rafael Fonseca1, Tania Jain2.   

Abstract

A dynamic approach to use bisphosphonates according to biomarkers of bone metabolism is presented in the Z-MARK study by Raje and colleagues. This is a major step forward toward a rational approach to bisphosphonate usage. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26792259      PMCID： PMC4794396          DOI： 10.1158/1078-0432.CCR-15-2981

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

2.  Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition.

Authors:  G W Gordon; J Monge; M B Channon; Q Wu; J L Skulan; A D Anbar; R Fonseca
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

Review 3.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

Review 4.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

5.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

6.  Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Authors:  J R Berenson; L S Rosen; A Howell; L Porter; R E Coleman; W Morley; R Dreicer; S A Kuross; A Lipton; J J Seaman
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

7.  Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

Authors:  Ashraf Badros; Dianna Weikel; Andrew Salama; Olga Goloubeva; Abraham Schneider; Aaron Rapoport; Robert Fenton; Natalie Gahres; Edward Sausville; Robert Ord; Timothy Meiller
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

8.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

Authors:  J R Berenson; A Lichtenstein; L Porter; M A Dimopoulos; R Bordoni; S George; A Lipton; A Keller; O Ballester; M J Kovacs; H A Blacklock; R Bell; J Simeone; D J Reitsma; M Heffernan; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Authors:  Robert A Kyle; Gary C Yee; Mark R Somerfield; Patrick J Flynn; Susan Halabi; Sundar Jagannath; Robert Z Orlowski; David G Roodman; Patricia Twilde; Kenneth Anderson
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544

10.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.